XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. Financing When it comes to looking to the future in the drug discovery industry, an important question to ask is: Where is the money?

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

DECEMBER 18, 2023

It is caused by GDF15, a hormone produced by the foetus. The international team from the University of Cambridge, Scotland, the USA and Sri Lanka used a combination of approaches including human genetics, new ways of measuring hormones in pregnant women’s blood, and studies in cells and mice.

Scientist 52

Scientist Hormones Genetics Development 52

XTalks

MARCH 28, 2024

Causes and Risk Factors for Endometriosis As the exact cause of endometriosis remains unclear, many potential causes are being proposed, including retrograde menstruation (where menstrual blood flows back into the pelvic cavity instead of leaving the body), immune system disorders and hormonal imbalances.

Hormones 40

Hormones Life Science In-Vitro Drugs 40

Pharma Packaging Solutions

JUNE 30, 2023

Biopharmaceuticals, also called biologics, are drug products that are manufactured using biological sources. Hormones (such as insulin, glucagon, and growth hormone, to name a few) are produced by recombinant DNA, as are blood factors, thrombolytic agents, interferons, monoclonal antibodies, therapeutic enzymes, and more.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

pharmaphorum

AUGUST 16, 2022

AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marketing application is approved by the FDA. months and 16.6 months, respectively. billion in the first half of this year.

Hormones 109

Hormones Gene Sales Trials 109

XTalks

MARCH 7, 2024

In a pivotal move for the food industry, the US Food and Drug Administration (FDA) has unveiled industry guidance for genome edited foods derived from plants. The team talks about the differences between genetically modified organisms (GMO) and gene edited foods, as well as whether these foods could be considered organic.

Gene Editing 52

Gene Editing Gene Genome Genomics 52

Roots Analysis

OCTOBER 24, 2023

Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

The Pharma Data

NOVEMBER 21, 2021

Food and Drug Administration approved Voxzogo (vosoritide) injection to improve growth in children five years of age and older with achondroplasia and open epiphyses (growth plates), meaning these children still have the potential to grow. director of the Division of General Endocrinology in the FDA’s Center for Drug Evaluation and Research.

FDA Approval 52

FDA Approval Drugs Regulation Genetics 52

Drug Discovery World

APRIL 6, 2023

Men in England and Wales with advanced, incurable prostate cancer who have BRCA1/2 mutations in their tumours and who have seen their cancer progress despite hormone therapy will also have access to olaparib. NICE previously decided not to recommend the drug as a prostate cancer treatment due to the high cost of genetic testing.

Hormones 52

Hormones Gene Scientist Licensing 52

Delveinsight

DECEMBER 29, 2020

Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. However, for geographies other than the US and Canada, Pfizer has received an exclusive right to develop the drug in oncology except in certain Asian countries. Welcome the First Generic of Drug for Severe Hypoglycemia.

Trials 52

Trials Drugs Hormones Radiology 52

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. GSK’s Benlysta (belimumab) is a monoclonal antibody that was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of SLE.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

pharmaphorum

SEPTEMBER 24, 2021

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug’s use broadened after a positive phase 3 trial. The two companies said they intend to share the new data with regulatory authorities “as soon as possible.”

Hormones 52

Hormones Genetics Sales Drugs 52

Drug Discovery World

APRIL 4, 2023

The Food and Drug Administration (FDA) in the US has made several key drug decisions over the last few weeks. The drug was granted orphan drug designation by the FDA in May 2021. The drug is expected to become a standard of care for these patients, who have had limited treatment options, according to analysts GlobalData.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

The Pharma Data

DECEMBER 17, 2020

7, 2020 — After starting a drug that’s officially approved to treat a type of blood cancer, a young man with type 1 diabetes was able to stop using insulin. 8 issue of the New England Journal of Medicine — stopped short of calling the drug a cure for type 1 diabetes. WEDNESDAY, Oct.

Insulin 52

Insulin Genetics Doctors Doctor 52

Trialfacts

NOVEMBER 23, 2022

Achondroplasia (ACH) is a genetic condition that affects children’s growth. CNP is a hormone produced by the body that plays an important role in the bone growth of children. CNP is a hormone produced by the body that plays an important role in the bone growth of children. Must not have a history of drug or alcohol abuse.

Clinical Trials 52

Clinical Trials Clinical Trials Hormones Research 52

Delveinsight

AUGUST 31, 2021

FDA’s Green Flag to Ascendis’s Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency. Growth Hormone Deficiency , commonly known as dwarfism, can constitute short stature and complications with metabolism, which arise due to inadequate production of growth hormones by the pituitary gland inside the body.

Hormones 60

Hormones FDA Approval Development Drugs 60

Delveinsight

SEPTEMBER 27, 2021

Furthermore, the condition carries the risk of differential diagnosis as more than 50 genetic/metabolic diseases are associated with infantile spasms, and many patients have other disorders that cause developmental delays (e.g., On the other hand, Antiepileptic Drugs (AEDs) form the second-line of treatment for West Syndrome patients.

Marketing 77

Marketing Hormones Radiology Pharma Companies 77

XTalks

AUGUST 15, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday that the US Food and Drug Administration (FDA) has granted marketing authorization for its combination treatment Akeega for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations. In April 2016, Janssen Biotech, Inc.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

Trialfacts

JANUARY 28, 2024

Individuals aged 18 to 30 years who are diagnosed with Bipolar I Disorder or Bipolar II Disorder Must be currently taking lithium Must not have colour blindness Must not be using drugs for recreational purposes and be willing to refrain from using for 4 weeks before enrolment Must not be working on a shift schedule or have travelled internationally (..)

Research 52

Research Hormones Genetics Drugs 52

Delveinsight

JULY 30, 2020

The buildup in adrenal glands leads to the insufficient hormonal response, thus leading to several of the symptoms such as deficiency of steroid hormones (mainly cortisol and aldosterone), impaired cortisol secretion, and others that are harbingers of the disease. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

XTalks

SEPTEMBER 17, 2020

Surrogate endpoints were used as the basis for approval of 45 percent of new drugs reviewed by the FDA between 2010 and 2012. For example, studies of heart attack prevention medications use the surrogate endpoint of low-density lipoprotein cholesterol (LDL-C) to assess the effectiveness of new drugs. What Is a Surrogate Endpoint?

Trials 98

Trials Gene Hormones Clinical Trials 98

Olympian Clinical Research

DECEMBER 19, 2023

Medications: Some medications, including certain anti-malarial drugs, beta-blockers, and lithium, can induce or exacerbate psoriasis. Family History: Genetics plays a significant role. Hormonal Changes: Hormonal fluctuations, especially during puberty, can influence the severity and onset of psoriasis.

Clinical Research 52

Clinical Research Hormones Clinical Trials Clinical Trials 52

XTalks

MARCH 13, 2024

Therapeutic Developments Related to Glaucoma The introduction of new classes of glaucoma medications, such as prostaglandin analogs, nitric oxide-donating drugs and Rho kinase inhibitors, has added to the pharmacological options available for managing IOP.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2?) Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. WELIREG can render some hormonal contraceptives ineffective.

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Hannelius said this highlights the importance of genetics when developing therapies for type 1 diabetes. “It

Vaccination 103

Vaccination Vaccine Insulin Trials 103

The Pharma Data

JANUARY 7, 2021

With eight drugs awaiting regulatory approval and 26 projects in Phase III studies, Sanofi is on the cusp of a transformative year during 2021. Another area where Sanofi is investing is through the Expanded Genetic Alphabet platform it gained at the end of 2019 through the $2.5 ricochet64/Shutterstock. billion acquisition of Synthorx.

Protein 52

Protein Antibody Genetics Gene Therapy 52

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Unlike conventional cancer drugs Vitravki can be used in tumours with this mutation regardless of whether they are in the body.

Marketing 94

Marketing Gene Silencing Gene Drugs 94

Delveinsight

JANUARY 7, 2021

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs. Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The newer side of the pipeline points targeted oncology drugs. Terns raises USD 87 Million for NASH drugs. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

JUNE 2, 2023

Food and Drug Administration (FDA) for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). This approval reinforces the importance of routine testing for genetic mutations at metastatic diagnosis to help guide clinical decisions.”

FDA Approval 52

FDA Approval HR Trials Hormones 52

The Pharma Data

DECEMBER 15, 2020

The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools. The Diamyd Medical data includes relevant information about disease progression, drug effects and clinical trial design.

Development 40

Development Insulin Drugs Clinical Trials 40

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

MAY 17, 2023

Astellas Pharma recently announced the US Food and Drug Administration (FDA) approval of their new medication, Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms.

Hormones 95

Hormones FDA Approval Drugs Clinical Trials 95

The Pharma Data

DECEMBER 9, 2020

Our focus on partnering to accelerate patient access to innovative medicines underscores our commitment to advancing breakthroughs in biomedicine such as antibody drug conjugates, cell therapy, RNAi and more, Ed Zhang, company co-founder, chief operating and business officer, said in a statement. “We

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Drug Discovery World

FEBRUARY 20, 2023

In April, the World Health Organisation (WHO) recommended Pfizer’s oral antiviral drug for patients with non-severe Covid-19 who are at highest risk of hospitalisation, based on data from two trials involving 3,100 patients.

Drug Trials 52

Drug Trials Trials Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 11, 2021

“Babies cannot shiver, and so when they are cold they would activate the brown fat and stay warm that way,” said Ruth Loos, director of the Genetics of Obesity and Related Metabolic Traits Program at the Charles R. Bronfman Institute of Personalized Medicine with the Icahn School of Medicine at Mount Sinai, in New York City.

Medicine 52

Medicine Research Hormones Genetics 52